Articles
Rheumatoid arthritis is one of the more common autoimmune diseases. LeadDiscovery’s recent state of the art evaluation of rheumatoid arthritis therapeutics evaluates advances in our understanding of the etiology of the disease. One field of research extensively analyzed in this report is angiogenesis. Inhibitors of receptor tyrosine kinase with specific activity against the VEGFRs have been developed in an attempt to prevent angiogenesis. One such molecule is PTK787/ZK222584, synthesized and dev
Rheumatoid arthritis (RA) is one of the more common autoimmune diseases affecting approximately 5 million individuals in the Western world. As described in LeadDiscovery’s state of the art evaluation of rheumatoid arthritis therapeutics (click here), this field is attracting massive interest in the…
Rheumatoid arthritis (RA) is one of the more common autoimmune diseases affecting approximately 5 million individuals in the Western world. As described in LeadDiscovery’s state of the art evaluation of rheumatoid arthritis therapeutics (click here), this field is attracting massive interest in the…
27-Aug-2010
‘To change Career, or to change Company?’ Although these seven words are easy to utter (and utter you will, over and over again), they are actually very deceptive as really what you are asking is, ‘Which direction should my life now take?’
Consider these statements: 1. I enjoy what I’m doing at the moment, but I often wonder if I would be better suited to something else 2. Although I have a good Idea of what I want to achieve, I have no motivation to get there. 3. I’ve worked at this company for a long time, and am very comfortable, but I’m not sure what else there is for me to do here. If you recognise any of these statements then it is highly likely you have reached the ‘Career Crossroads’. Although it sounds like a kind of Career Mid-life crisis it really isn’…
Consider these statements: 1. I enjoy what I’m doing at the moment, but I often wonder if I would be better suited to something else 2. Although I have a good Idea of what I want to achieve, I have no motivation to get there. 3. I’ve worked at this company for a long time, and am very comfortable, but I’m not sure what else there is for me to do here. If you recognise any of these statements then it is highly likely you have reached the ‘Career Crossroads’. Although it sounds like a kind of Career Mid-life crisis it really isn’…
An estimated 5 million individuals suffer from rheumatoid arthritis. Corticosteroids are the most dramatically effective short-term anti-inflammatory drugs; however, clinical benefit for rheumatoid arthritis often diminishes with time. Because of their long-term systemic side effects, corticosteroids are usually given only after a careful and prolonged trial of less hazardous drugs. Liposomes are artificial vesicles efficiently phagocytosed by macrophages and recent advances such as the developm
Rheumatoid arthritis is one of the more common autoimmune diseases along with multiple sclerosis, type I diabetes and Crohn’s disease. Approximately one in five people in the western world suffer from autoimmune diseases and some estimates indicate that 75% of these are women. In total it is predict…
Rheumatoid arthritis is one of the more common autoimmune diseases along with multiple sclerosis, type I diabetes and Crohn’s disease. Approximately one in five people in the western world suffer from autoimmune diseases and some estimates indicate that 75% of these are women. In total it is predict…
The R&D activity surrounding novel oral treatments of diabetes is considerable and one particular target that has recently received attention is the Kv1.3 potassium channel. Blocking this channel has been thought to be of value in the treatment of multiple sclerosis and more recently for preventing weight gain. Now researchers from Yale have demonstrated that Kv1.3 channel blockers may also increase insulin sensitivity in genetically obese and diabetic mice
According to WHO, there are some 130 million diagnosed diabetics in the world, a figure that is predicted to increase to 300 million by 2025. The market for diabetes therapeutics is also rising with global sales reportedly topping $8.1 billion for the 12 months to September 2000, a 19% increase over the previous 12 months (for a full ana…
According to WHO, there are some 130 million diagnosed diabetics in the world, a figure that is predicted to increase to 300 million by 2025. The market for diabetes therapeutics is also rising with global sales reportedly topping $8.1 billion for the 12 months to September 2000, a 19% increase over the previous 12 months (for a full ana…
Pulmonary arterial hypertension (PAH) represents an unmet market. Initial breakthroughs in treatment focussed on the rare form of this condition, idiopathic pulmonary arterial hypertension. Recently however a key advance in the treatment of PAH was made with the launch of Actelion's twice-daily Tracleer (bosentan) as the first orally active treatment of both idiopathic and secondary PAH. Tracleer is the first generation of a class of drugs known as endothelin receptor antagonists and blocks two
Pulmonary arterial hypertension (PAH) exists in a rare idiopathic or unexplained form (which occurs in familial and sporadic forms) called idiopathic pulmonary arterial hypertension (IPAH, previously referred to as primary pulmonary hypertension, PPH)) and a relatively common form of secondary pulmo…
Pulmonary arterial hypertension (PAH) exists in a rare idiopathic or unexplained form (which occurs in familial and sporadic forms) called idiopathic pulmonary arterial hypertension (IPAH, previously referred to as primary pulmonary hypertension, PPH)) and a relatively common form of secondary pulmo…
27-Aug-2010
Everyone knows that first impressions count. There have been countless articles on how to ‘Dress to impress’, and how to make sure the first five minutes of your interview are geared towards creating the perfect ‘First Impression’.
Everyone knows that first impressions count. There have been countless articles on how to ‘Dress to impress’, and how to make sure the first five minutes of your interview are geared towards creating the perfect ‘First Impression’. But what about last impressions? Is saying goodbye less important that saying hello? When the interview is over, and you jump up from you chair declaring that you’re ‘Glad that’s over, as I’m desperate to head off down the pub to catch the game’, or ‘I’m happy the interview is finished as I’ve had loads of interviews this week, and…
Everyone knows that first impressions count. There have been countless articles on how to ‘Dress to impress’, and how to make sure the first five minutes of your interview are geared towards creating the perfect ‘First Impression’. But what about last impressions? Is saying goodbye less important that saying hello? When the interview is over, and you jump up from you chair declaring that you’re ‘Glad that’s over, as I’m desperate to head off down the pub to catch the game’, or ‘I’m happy the interview is finished as I’ve had loads of interviews this week, and…
Numerous inflammatory mediators have been implicated in the etiology of asthma. Blocking specific inflammatory mediators has frequently yielded unimpressive clinical results and instead the simultaneous targeting or more than one mediator may be of greater use. In the current edition of LeadDiscovery's TherapeuticAdvances work by researchers at UCB who have developed a dual 5-LO inhibitor/H1 receptor antagonist is highlighted
The incidence of asthma has dramatically increased over recent years and although currently available treatments are generally effective, patient compliance is currently poor, especially with respect to inhaled treatment. Furthermore, 5% of patients are unresponsive to these treatments and it is this cohort that accounts for a large segment of asthma related healthcare…
The incidence of asthma has dramatically increased over recent years and although currently available treatments are generally effective, patient compliance is currently poor, especially with respect to inhaled treatment. Furthermore, 5% of patients are unresponsive to these treatments and it is this cohort that accounts for a large segment of asthma related healthcare…
PABORD is the first exhibition and conference dedicated to Outsourcing in Research and Development for the Pharmaceutical and Biotechnology industries.
PABORD is the first exhibition and conference dedicated to Outsourcing in Research and Development for the Pharmaceutical and Biotechnology industries. With an international line-up of renowned speakers, thiscutting-edge new event is taking place at London's ExCel conference and exhibition venue on September 28th and 29th 2004. Almost 200 companies will be participating at PABORD, Europe's first show that focuses completely on the rapidly expanding trend towards outsourcing in the research and development of new therapeutics. PABORD is extremely well timed, considering how this new trend is having such an increasinglyprofound effect on the…
PABORD is the first exhibition and conference dedicated to Outsourcing in Research and Development for the Pharmaceutical and Biotechnology industries. With an international line-up of renowned speakers, thiscutting-edge new event is taking place at London's ExCel conference and exhibition venue on September 28th and 29th 2004. Almost 200 companies will be participating at PABORD, Europe's first show that focuses completely on the rapidly expanding trend towards outsourcing in the research and development of new therapeutics. PABORD is extremely well timed, considering how this new trend is having such an increasinglyprofound effect on the…
27-Aug-2010
As we all know, interviews come in three forms: The good, the bad, and sometimes… The downright ugly! This is an article about the latter; ugly interviews, from ‘unconventional’ interviewers, who wouldn’t know the words ‘Professional, Un-biased and Independent’ even if they came up and bit them!
As we all know, interviews come in three forms: The good, the bad, and sometimes… The downright ugly! This is an article about the latter; ugly interviews, from ‘unconventional’ interviewers, who wouldn’t know the words ‘Professional, Un-biased and Independent’ even if they came up and bit them! Take this article, as a guide to how to handle unprofessional interviews in a professional manner. First things first though, how do you know that your interview is an ‘Ugly’ interview and not just a ‘Bad’…
As we all know, interviews come in three forms: The good, the bad, and sometimes… The downright ugly! This is an article about the latter; ugly interviews, from ‘unconventional’ interviewers, who wouldn’t know the words ‘Professional, Un-biased and Independent’ even if they came up and bit them! Take this article, as a guide to how to handle unprofessional interviews in a professional manner. First things first though, how do you know that your interview is an ‘Ugly’ interview and not just a ‘Bad’…
Researchers have developed a series of assays to identify improved DDP-IV inhibitors for the treatment of diabetes and possibly cancer. The technology described here can also be applied to improving the oral absorption of poorly absorbed drugs in general
Glucagon like Peptide-1 (GLP-1) is a gut hormone released after food consumption to stimulate insulin secretion. GLP-1 has a very short half-life due to its degradation by the proteolytic enzyme dipeptidyl peptidase-IV (DPP-IV; CD26) which cleaves peptides after proline residues. Therefore, specific inhibition of DPP-IV is an attractive therapeutic approach to stimulate glucose dependent insulin secretion. In addition to its role in glucose homeostasis, DPP-IV has been implicated in immune disorders, HIV-1 infection and tumor progression a…
Glucagon like Peptide-1 (GLP-1) is a gut hormone released after food consumption to stimulate insulin secretion. GLP-1 has a very short half-life due to its degradation by the proteolytic enzyme dipeptidyl peptidase-IV (DPP-IV; CD26) which cleaves peptides after proline residues. Therefore, specific inhibition of DPP-IV is an attractive therapeutic approach to stimulate glucose dependent insulin secretion. In addition to its role in glucose homeostasis, DPP-IV has been implicated in immune disorders, HIV-1 infection and tumor progression a…
27-Aug-2010
Pharma NewsBytes selects out some of the most interesting press releases to have appeared on LeadDiscovery’s DailyUpdates tracking service over the past few weeks. This edition includes an update on selected releases from the American Society of Clinical Oncology and the American Diabetes Association as well as important news concerning the antipsychotic, Abilify (Aripiprazole) and novel HIV treatments
With several blockbuster biological products approaching patent expiry and the emergence of new approval pathways, the biogenerics segment represents an attractive opportunity for companies looking to escape intensifying competition in the commodity generics sector. However, with the biotech industry preparing significant opposition to any new regulatory initiatives, barriers to market entry could remain high.
In the report 'Biogenerics: Drivers and Resistors of Market Development', Datamonitor evaluates developments in the regulatory environment for biogenerics in the US and EU. The research also analyzes possible market entry strategies and assesses the market potential of biogenerics, and the barriers to companies wishing to enter the industry. Growing demand for biogenerics Despite st…
In the report 'Biogenerics: Drivers and Resistors of Market Development', Datamonitor evaluates developments in the regulatory environment for biogenerics in the US and EU. The research also analyzes possible market entry strategies and assesses the market potential of biogenerics, and the barriers to companies wishing to enter the industry. Growing demand for biogenerics Despite st…
27-Aug-2010
This conference clarifies the risks that impede healthy practice, knowledgeable planning, and profits from off-label usage.
Off-label usage of drugs and medical devices accounts for a large percentage of profits yet also presents a minefield of potential legal, regulatory, ethical, and financial problems. To make matters worse, the regulatory and legal landscape has become more varied and confusing in recent years as organizations such as the DOJ, the OIG, and more have become involved. Here’s a chance for you to learn everything you need to know about this difficult topic in one easy stop. This conference addresses the following issues (and more): · Understanding and complying with the FDA on off-label issues · …
Off-label usage of drugs and medical devices accounts for a large percentage of profits yet also presents a minefield of potential legal, regulatory, ethical, and financial problems. To make matters worse, the regulatory and legal landscape has become more varied and confusing in recent years as organizations such as the DOJ, the OIG, and more have become involved. Here’s a chance for you to learn everything you need to know about this difficult topic in one easy stop. This conference addresses the following issues (and more): · Understanding and complying with the FDA on off-label issues · …
27-Aug-2010
To aid in your drug development efforts, Pharmaceutical Education Associates is proud to present our inaugural “Identification and Validation of Safety and Efficacy Biomarkers” conference. Ultimately, the drug discovery process must be a collaborative one, drawing together researchers from industry, academia, and government agencies to identify and address all possible benefits and consequences. In that spirit, our top-notch speaking faculty brings together experts from all these groups to add
With the advent of powerful, new genomic and proteomic technologies, it should be easy to identify potential biomarkers of safety and efficacy. It should be possible to develop a systematic approach to discover, develop, and validate biomarkers that bridge from pre-clinical evaluations to clin…
With the advent of powerful, new genomic and proteomic technologies, it should be easy to identify potential biomarkers of safety and efficacy. It should be possible to develop a systematic approach to discover, develop, and validate biomarkers that bridge from pre-clinical evaluations to clin…
DailyUpdates 20th April: Nearly 423,000 new cases of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are expected to have been diagnosed in the seven major pharmaceutical markets in 2003. Despite the high level of pharmaceutical interest, there are significant unmet needs in the disease in terms of poor survival. Docetaxel is the only drug currently approved in both the U.S. and Europe to treat patients with non-small cell lung cancer in the second-line setting. While the dr
DailyUpdates 20th April: Nearly 423,000 new cases of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are expected to have been diagnosed in the seven major pharmaceutical markets in 2003. Despite the high level of pharmaceutical interest, there are significant unmet needs i…
DailyUpdates 20th April: Nearly 423,000 new cases of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are expected to have been diagnosed in the seven major pharmaceutical markets in 2003. Despite the high level of pharmaceutical interest, there are significant unmet needs i…
DailyUpdates 11th May: A number of clinical studies including the VIGOR trial have suggested that the NSAID naproxen may reduce the incidence of myocardial infarction. However the gastrointestinal side-effects of naproxen and its ability to exacerbate hypertension preclude its use in at-risk individuals. Upcoming data about to be published in the journal JPET demonstrate the efficacy of the safer and anti-hypertensive nitro-derivative of naproxen, HCT 3012, in a model of myocardial infarction.
DailyUpdates 11th May: A number of clinical studies including the VIGOR trial have suggested that the NSAID naproxen may reduce the incidence of myocardial infarction. However the gastrointestinal side-effects of naproxen and its ability to exacerbate hypertension preclude its use in at-r…
DailyUpdates 11th May: A number of clinical studies including the VIGOR trial have suggested that the NSAID naproxen may reduce the incidence of myocardial infarction. However the gastrointestinal side-effects of naproxen and its ability to exacerbate hypertension preclude its use in at-r…
DailyUpdates 10th May: Last week European regulators affirmed the safety of Celebrex; good news for Pfizer continues with the emergence of data from the PACES trials reporting that, compared to acetaminophen, Celebrex is both preferred by patients and is of greater efficacy.
DailyUpdates 10th May: Last week European regulators affirmed the safety of Celebrex; good news for Pfizer continues with the emergence of data from the PACES trials reporting that, compared to acetaminophen, Celebrex is both preferred by patients and is of greater efficacy. Osteoarthritis is characterized by the degeneration of the articular cartilage and is the most prevalent form of arthritis, affecting 10% of the population, equating to a patient population of over 73 million people in the seven major pharmaceutica…
DailyUpdates 10th May: Last week European regulators affirmed the safety of Celebrex; good news for Pfizer continues with the emergence of data from the PACES trials reporting that, compared to acetaminophen, Celebrex is both preferred by patients and is of greater efficacy. Osteoarthritis is characterized by the degeneration of the articular cartilage and is the most prevalent form of arthritis, affecting 10% of the population, equating to a patient population of over 73 million people in the seven major pharmaceutica…
Learn innovative ways to analyze data derived from signals in clinical development as well as post-maketing surveillance.
Pharmaceutical Education Associates Presents: Signal Detection throughout the Product Life Cycle – The Park Hyatt at the – Pharmaceutical companies have been tracking adverse events, drug reactions and drug safety issues for years. Now, the most successful companies are implementing innovative methods and ways of data mining into complex, multi-faceted databases to proactively identify and analyze signals that occur not only in post-marketing surveillance, but in all phases of drug development as well. Even the regulatory agencies like the FDA are developing new recommendations for analyzing data that will help in identifying signals earlier – even in…
Pharmaceutical Education Associates Presents: Signal Detection throughout the Product Life Cycle – The Park Hyatt at the – Pharmaceutical companies have been tracking adverse events, drug reactions and drug safety issues for years. Now, the most successful companies are implementing innovative methods and ways of data mining into complex, multi-faceted databases to proactively identify and analyze signals that occur not only in post-marketing surveillance, but in all phases of drug development as well. Even the regulatory agencies like the FDA are developing new recommendations for analyzing data that will help in identifying signals earlier – even in…
27-Aug-2010
This edition of Emerging Drug Discovery Targets features MBD2 inhibitors as a selective strategy for reducing tumor growth; NicOx's NO-ASA cancer candidate, NCX 4040, MIF as a target for atherogenesis; expanding indications for COX-2 inhibitors; and a dual MMP and TACE inhibitor as a treatment of rheumatoid arthritis. This edition also sees a new section "TherapyUpdate" which this month focuses on Osteoporosis. As usual we also provide updates on industrial advances and licensing opportunities a
Emerging Drug Discovery Targets from LeadDiscovery 6th May 2004 to view this alert on line please go to http://www.leaddiscovery.co.uk/TherapeuticAdvances%20Archive/May%206th%20emerging%20targets.htm ************************************** "Emerging Drug Discovery Targets" provides a twice monthly su…
Emerging Drug Discovery Targets from LeadDiscovery 6th May 2004 to view this alert on line please go to http://www.leaddiscovery.co.uk/TherapeuticAdvances%20Archive/May%206th%20emerging%20targets.htm ************************************** "Emerging Drug Discovery Targets" provides a twice monthly su…
27-Aug-2010
Join Dr Philip Wright, Director of Science at the ABPI live online to find out.
Medicines wants to know:"Why has there been a decline in interest in science, maths and technology?" Dr Philip Wright said: Well there's not really any single explanation about why there's been a decline what we're most concerned about actually are chemistry courses and attracting young people to take part. In part because somehow we're missing the excitement of practical science that's the thing that attracted me to science. In chemistry we're seeing a situation where over 70% of GCSE chemistry classes are taken by teachers without a chemistry degree. Which is a bit worrying. Somehow we have to attract students to do chemistry degrees and then some of those graduates need to teaching. Sasha wan…
Medicines wants to know:"Why has there been a decline in interest in science, maths and technology?" Dr Philip Wright said: Well there's not really any single explanation about why there's been a decline what we're most concerned about actually are chemistry courses and attracting young people to take part. In part because somehow we're missing the excitement of practical science that's the thing that attracted me to science. In chemistry we're seeing a situation where over 70% of GCSE chemistry classes are taken by teachers without a chemistry degree. Which is a bit worrying. Somehow we have to attract students to do chemistry degrees and then some of those graduates need to teaching. Sasha wan…
